Mitochondria are central for cancer responses to therapy-induced stress signals. Refractory tumors often show attenuated sensitivity to apoptotic signaling, yet clinically relevant molecular actors to target mitochondria-mediated resistance remain elusive. Here, we show that MYC-driven neuroblastoma cells rely on intact mitochondrial ribosome (mitoribosome) processivity and undergo cell death following pharmacological inhibition of mitochondrial translation, regardless of their multidrug/mitochondrial resistance and stem-like phenotypes. Mechanistically, inhibiting mitoribosomes induced the mitochondrial stress-activated integrated stress response (ISR), leading to downregulation of c-MYC/N-MYC proteins prior to neuroblastoma cell death, which could be both rescued by the ISR inhibitor ISRIB. The ISR blocks global protein synthesis and shifted the c-MYC/N-MYC turnover toward proteasomal degradation. Comparing models of various neuroectodermal tumors and normal fibroblasts revealed overexpression of MYC proteins phosphorylated at the degradation-promoting site T58 as a factor that predetermines vulnerability of MYC-driven neuroblastoma to mitoribosome inhibition. Reducing N-MYC levels in a neuroblastoma model with tunable MYCN expression mitigated cell death induction upon inhibition of mitochondrial translation and functionally validated the propensity of neuroblastoma cells for MYC-dependent cell death in response to the mitochondrial ISR. Notably, neuroblastoma cells failed to develop significant resistance to the mitoribosomal inhibitor doxycycline over a long-term repeated (pulsed) selection. Collectively, we identify mitochondrial translation machinery as a novel synthetic lethality target for multidrug-resistant MYC-driven tumors.

Bill Walsh Translational Cancer Research Laboratory Kolling Institute Faculty of Medicine and Health The University of Sydney St Leonards NSW 2065 Australia

Cancer Drug Resistance and Stem Cell Program School of Medical Science Faculty of Medicine and Health The University of Sydney Camperdown NSW 2006 Australia

Department of Experimental Biology Faculty of Science Masaryk University 62500 Brno Czech Republic

Department of Pediatrics Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

Division of Oncology and Center for Childhood Cancer Research The Children's Hospital of Philadelphia Philadelphia PA USA

International Clinical Research Center St Anne's University Hospital 65691 Brno Czech Republic

See more in PubMed

Skoda J, Borankova K, Jansson PJ, Huang MLH, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: an ancient organelle at the crossroad of novel anti-cancer therapies. Pharm Res. 2019;139:298–313. doi: 10.1016/j.phrs.2018.11.020. PubMed DOI

Guerra F, Arbini AA, Moro L. Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg. 2017;1858:686–99. doi: 10.1016/j.bbabio.2017.01.012. PubMed DOI

Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21:85–100. doi: 10.1038/s41580-019-0173-8. PubMed DOI

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study. Br J Cancer. 2015;113:57–63. doi: 10.1038/bjc.2015.188. PubMed DOI PMC

Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the Children’s Oncology Group. J Clin Oncol. 2021;39:3229–41. doi: 10.1200/JCO.21.00278. PubMed DOI PMC

Graves JA, Wang YD, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, et al. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS ONE. 2012;7:13. doi: 10.1371/journal.pone.0037699. PubMed DOI PMC

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, et al. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget. 2016;7:72395–414. doi: 10.18632/oncotarget.11718. PubMed DOI PMC

Zeineldin M, Federico S, Chen X, Fan YP, Xu BS, Stewart E, et al. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020;11:20. doi: 10.1038/s41467-020-14682-6. PubMed DOI PMC

Popay TM, Wang J, Adams CM, Howard GC, Codreanu SG, Sherrod SD, et al. MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1. eLife. 2021;10:39. doi: 10.7554/eLife.60191. PubMed DOI PMC

Oliynyk G, Ruiz-Perez MV, Sainero-Alcolado L, Dzieran J, Zirath H, Gallart-Ayala H, et al. MYCN-enhanced oxidative and glycolytic metabolism reveals vulnerabilities for targeting neuroblastoma. iScience. 2019;21:188–204. doi: 10.1016/j.isci.2019.10.020. PubMed DOI PMC

Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22:427–32. doi: 10.1038/nm.4055. PubMed DOI PMC

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–U100. doi: 10.1038/nature07823. PubMed DOI PMC

Coku J, Booth DM, Skoda J, Pedrotty MC, Vogel J, Liu KN, et al. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO J. 2022;41:20. doi: 10.15252/embj.2021108272. PubMed DOI PMC

Viale A, Pettazzoni P, Lyssiotis CA, Ying HQ, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628–32. doi: 10.1038/nature13611. PubMed DOI PMC

Veiga SR, Ge XM, Mercer CA, Hernandez-Alvarez MI, Thomas HE, Hernandez-Losa J, et al. Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR. Clin Cancer Res. 2018;24:3767–80. doi: 10.1158/1078-0432.CCR-18-0177. PubMed DOI

Jiang W, Finniss S, Cazacu S, Xiang C, Brodie Z, Mikkelsen T, et al. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget. 2016;7:56456–70. doi: 10.18632/oncotarget.10919. PubMed DOI PMC

Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015;18:501–10. doi: 10.1038/nn.3960. PubMed DOI PMC

Vendramin R, Katopodi V, Cinque S, Konnova A, Knezevic Z, Adnane S, et al. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. J Exp Med. 2021;218:e20210571. doi: 10.1084/jem.20210571. PubMed DOI PMC

Quirós PM, Mottis A, Auwerx J. Mitonuclear communication in homeostasis and stress. Nat Rev Mol Cell Biol. 2016;17:213–26. doi: 10.1038/nrm.2016.23. PubMed DOI

Guo XY, Aviles G, Liu Y, Tian RL, Unger BA, Lin YHT, et al. Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway. Nature. 2020;579:427–32. doi: 10.1038/s41586-020-2078-2. PubMed DOI PMC

Fessler E, Eckl EM, Schmitt S, Mancilla IA, Meyer-Bender MF, Hanf M, et al. A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol. Nature. 2020;579:433–7. doi: 10.1038/s41586-020-2076-4. PubMed DOI PMC

Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer. 1997;33:2002–6. doi: 10.1016/S0959-8049(97)00213-X. PubMed DOI

Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–29. doi: 10.1038/nrclinonc.2017.44. PubMed DOI PMC

Skoda J, Neradil J, Zambo IS, Nunukova A, Macsek P, Borankova K, et al. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. Cancers. 2020;12:24. doi: 10.3390/cancers12010196. PubMed DOI PMC

Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–94. doi: 10.1002/ijc.28475. PubMed DOI

Yao CH, Liu GY, Wang R, Moon SH, Gross RW, Patti GJ. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation. PLoS Biol. 2018;16:e2003782. doi: 10.1371/journal.pbio.2003782. PubMed DOI PMC

Raud B, Roy DG, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, et al. Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. Cell Metab. 2018;28:504–515.e507. doi: 10.1016/j.cmet.2018.06.002. PubMed DOI PMC

Di Magno L, Manni S, Di Pastena F, Coni S, Macone A, Cairoli S, et al. Phenformin inhibits hedgehog-dependent tumor growth through a complex I-independent redox/corepressor module. Cell Rep. 2020;30:1735–1752.e1737. doi: 10.1016/j.celrep.2020.01.024. PubMed DOI

García Rubiño ME, Carrillo E, Ruiz Alcalá G, Domínguez-Martín A, Marchal JA, Boulaiz H. Phenformin as an anticancer agent: challenges and prospects. Int J Mol Sci. 2019;20:3316. doi: 10.3390/ijms20133316. PubMed DOI PMC

Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002;36:1–12. doi: 10.1067/mva.2002.125018. PubMed DOI

Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35:923–8. doi: 10.1067/mva.2002.123757. PubMed DOI

Todd SR, Dahlgren FS, Traeger MS, Beltrán-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr. 2015;166:1246–51. doi: 10.1016/j.jpeds.2015.02.015. PubMed DOI

Pöyhönen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lähdesmäki T. Dental staining after doxycycline use in children. J Antimicrob Chemother. 2017;72:2887–90. doi: 10.1093/jac/dkx245. PubMed DOI PMC

Lima T, Li TY, Mottis A, Auwerx J. Pleiotropic effects of mitochondria in aging. Nat Aging. 2022;2:199–213. doi: 10.1038/s43587-022-00191-2. PubMed DOI

Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, Mottis A, et al. Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research. Cell Rep. 2015;10:1681–91. doi: 10.1016/j.celrep.2015.02.034. PubMed DOI PMC

Houtkooper RH, Mouchiroud L, Ryu D, Moullan N, Katsyuba E, Knott G, et al. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature. 2013;497:451–7. doi: 10.1038/nature12188. PubMed DOI PMC

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20:674–88. doi: 10.1016/j.ccr.2011.10.015. PubMed DOI PMC

Wei SJ, Nguyen TH, Yang IH, Mook DG, Makena MR, Verlekar D, et al. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis. 2020;11:20. doi: 10.1038/s41419-020-2563-4. PubMed DOI PMC

Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC. EBioMedicine. 2022;75:103756. doi: 10.1016/j.ebiom.2021.103756. PubMed DOI PMC

Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015;4:6–13. doi: 10.1016/j.redox.2014.11.006. PubMed DOI PMC

Sprenger HG, Langer T. The good and the bad of mitochondrial breakups. Trends Cell Biol. 2019;29:888–900. doi: 10.1016/j.tcb.2019.08.003. PubMed DOI

Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, et al. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 2012;72:2565–77. doi: 10.1158/0008-5472.CAN-11-3603. PubMed DOI PMC

Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122:1544–51. doi: 10.1038/s41416-020-0795-9. PubMed DOI PMC

Rainbolt TK, Lebeau J, Puchades C, Wiseman RL. Reciprocal degradation of YME1L and OMA1 adapts mitochondrial proteolytic activity during stress. Cell Rep. 2016;14:2041–9. doi: 10.1016/j.celrep.2016.02.011. PubMed DOI PMC

Anderson NS, Haynes CM. Folding the mitochondrial UPR into the integrated stress response. Trends Cell Biol. 2020;30:428–39. doi: 10.1016/j.tcb.2020.03.001. PubMed DOI PMC

Baker MJ, Lampe PA, Stojanovski D, Korwitz A, Anand R, Tatsuta T, et al. Stress-induced OMA1 activation and autocatalytic turnover regulate OPA1-dependent mitochondrial dynamics. EMBO J. 2014;33:578–93. doi: 10.1002/embj.201386474. PubMed DOI PMC

Gilkerson R, De La Torre P, St Vallier S. Mitochondrial OMA1 and OPA1 as gatekeepers of organellar structure/function and cellular stress response. Front Cell Dev Biol. 2021;9:626117. doi: 10.3389/fcell.2021.626117. PubMed DOI PMC

Rainbolt TK, Saunders JM, Wiseman RL. YME1L degradation reduces mitochondrial proteolytic capacity during oxidative stress. EMBO Rep. 2015;16:97–106. doi: 10.15252/embr.201438976. PubMed DOI PMC

Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121–35. doi: 10.1038/nrm.2017.95. PubMed DOI PMC

Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12:446–51. doi: 10.1038/nm1388. PubMed DOI

Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374–95. doi: 10.15252/embr.201642195. PubMed DOI PMC

Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32:1284–95. doi: 10.1038/onc.2012.144. PubMed DOI

Bonvini P, Nguyen P, Trepel J, Neckers LM. In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome. Oncogene. 1998;16:1131–9. doi: 10.1038/sj.onc.1201625. PubMed DOI

Berra E, Roux D, Richard DE, Pouysségur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2001;2:615–20. doi: 10.1093/embo-reports/kve130. PubMed DOI PMC

Slomp A, Moesbergen LM, Eldering E, Kersten MJ, Minnema MC, Peperzak V. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Cell Death Dis. 2021;12:229. doi: 10.1038/s41419-020-03351-7. PubMed DOI PMC

Rooswinkel RW, van de Kooij B, de Vries E, Paauwe M, Braster R, Verheij M, et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood. 2014;123:2806–15. doi: 10.1182/blood-2013-08-519470. PubMed DOI

Franch HA, Sooparb S, Du J, Brown NS. A mechanism regulating proteolysis of specific proteins during renal tubular cell growth. J Biol Chem. 2001;276:19126–31. doi: 10.1074/jbc.M101777200. PubMed DOI

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14. doi: 10.1101/gad.836800. PubMed DOI PMC

Zyryanova AF, Kashiwagi K, Rato C, Harding HP, Crespillo-Casado A, Perera LA, et al. ISRIB blunts the integrated stress response by allosterically antagonising the inhibitory effect of phosphorylated eIF2 on eIF2B. Mol Cell. 2021;81:88–103.e106. doi: 10.1016/j.molcel.2020.10.031. PubMed DOI PMC

Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15:67–78. doi: 10.1016/j.ccr.2008.12.005. PubMed DOI

Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13:803–12. PubMed

Cimmino F, Pezone L, Avitabile M, Acierno G, Andolfo I, Capasso M, et al. Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. Sci Rep. 2015;5:15. doi: 10.1038/srep11158. PubMed DOI PMC

Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. Science. 2020;368:eaat5314. doi: 10.1126/science.aat5314. PubMed DOI PMC

Qing GL, Li B, Vu A, Skuli N, Walton ZE, Liu XY, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012;22:631–44. doi: 10.1016/j.ccr.2012.09.021. PubMed DOI PMC

Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38 alpha MAPK activation through ROS generation. Apoptosis. 2007;12:1733–42. doi: 10.1007/s10495-007-0082-8. PubMed DOI

Chen J, Chen JQ, Cheng YH, Fu YF, Zhao HZ, Tang MY, et al. Mesenchymal stem cell-derived exosomes protect beta cells against hypoxia-induced apoptosis via miR-21 by alleviating ER stress and inhibiting p38 MAPK phosphorylation. Stem Cell Res Ther. 2020;11:12. PubMed PMC

Ibraheem K, Yhmed AMA, Qayyum T, Bryan NP, Georgopoulos NT. CD40 induces renal cell carcinoma-specific differential regulation of TRAF proteins, ASK1 activation and JNK/p38-mediated, ROS-dependent mitochondrial apoptosis. Cell Death Discov. 2019;5:14. doi: 10.1038/s41420-019-0229-8. PubMed DOI PMC

Wang XZ, Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science. 1996;272:1347–9. doi: 10.1126/science.272.5266.1347. PubMed DOI

Sari FR, Widyantoro B, Thandavarayan RA, Harima M, Lakshmanan AP, Zhang SS, et al. Attenuation of CHOP-mediated myocardial apoptosis in pressure-overloaded dominant negative p38 alpha mitogen-activated protein kinase mice. Cell Physiol Biochem. 2011;27:487–96. doi: 10.1159/000329970. PubMed DOI

Lopez-Crisosto C, Diaz-Vegas A, Castro PF, Rothermel BA, Bravo-Sagua R, Lavandero S. Endoplasmic reticulum-mitochondria coupling increases during doxycycline-induced mitochondrial stress in HeLa cells. Cell Death Dis. 2021;12:12. doi: 10.1038/s41419-021-03945-9. PubMed DOI PMC

Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, et al. Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity. Oncogenesis. 2017;6:397. doi: 10.1038/s41389-017-0009-3. PubMed DOI PMC

Mortison JD, Schenone M, Myers JA, Zhang ZY, Chen LF, Ciarlo C, et al. Tetracyclines modify translation by targeting key human rRNA substructures. Cell Chem Biol. 2018;25:1506–1518.e13. doi: 10.1016/j.chembiol.2018.09.010. PubMed DOI PMC

Sanchez-Burgos L, Navarro-Gonzalez B, Garcia-Martin S, Sirozh O, Mota-Pino J, Fueyo-Marcos E, et al. Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells. EMBO Mol Med. 2022;14:18. doi: 10.15252/emmm.202215855. PubMed DOI PMC

D’Andrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A, et al. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. Oncotarget. 2016;7:72415–30. doi: 10.18632/oncotarget.11719. PubMed DOI PMC

Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994;14:5510–22. PubMed PMC

Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005;9:327–38. doi: 10.1016/j.devcel.2005.07.014. PubMed DOI

Young L, Sung J, Stacey G, Masters JR. Detection of Mycoplasma in cell cultures. Nat Protoc. 2010;5:929–34. doi: 10.1038/nprot.2010.43. PubMed DOI

Kameneva P, Melnikova VI, Kastriti ME, Kurtova A, Kryukov E, Murtazina A, et al. Serotonin limits generation of chromaffin cells during adrenal organ development. Nat Commun. 2022;13:21. doi: 10.1038/s41467-022-30438-w. PubMed DOI PMC

Valente AJ, Maddalena LA, Robb EL, Moradi F, Stuart JA. A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture. Acta Histochem. 2017;119:315–26. doi: 10.1016/j.acthis.2017.03.001. PubMed DOI

Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis. 2012;3:7. doi: 10.1038/cddis.2012.171. PubMed DOI PMC

Khader H, Solodushko V, Al-Mehdi AB, Audia J, Fouty B. Overlap of doxycycline fluorescence with that of the redox-sensitive intracellular reporter roGFP. J Fluoresc. 2014;24:305–11. doi: 10.1007/s10895-013-1331-6. PubMed DOI